Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by sah1on Jan 09, 2017 12:16pm
258 Views
Post# 25683440

RE:RE:revenue expectations management

RE:RE:revenue expectations managementBob, in order to get Pg revenues of $8-10m for 2017, PLI will need to get at least 320-400 patients signed up and on treatment very quickly as the cost of treatment for the balance of the year will be about $25 000/person if everyone starts July 1st. Since I expect the introduction of Pg to take time to implement even more patients may be required than noted above to achieve this revenue target for 2017. Perhaps I am being conservative but it seems I have always been overoptimistic when making revenue projections for PLI in the past. Let's see just how many Pg deficient patients PLI identifies and gets on treatment. In the interim, management has got to get a couple of regional partnership deals on 4050 across the line.

Bullboard Posts